Cytosorbents Corp (CTSO)

• Market cap: $66.7M
• 1 day: 0.00%
• 5 days: 0.94%
• 1 month: -18.32%
• 3 months: 5.94%
• 6 months: -0.93%
• Year to date: 16.30%
• 1 year: 5.94%
• 5 years: -76.59%
• 10 years: -91.01%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Employees: 186

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2.23% less ownership

Funds ownership: 30.18% [Q3] → 27.95% (-2.23%) [Q4]

4% less funds holding

Funds holding: 52 [Q3] → 50 (-2) [Q4]

42% less capital invested

Capital invested by funds: $24.6M [Q3] → $14.2M (-$10.4M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 835% upside
• Avg. target: $10 835% upside
• High target: $10 835% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target

835% upside $10

Buy Maintained

25 Feb 2025